Article
A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.
The Prostate - 1 Dec 2024
Boiarsky Daniel, Tewari Alok K, Gulhan Doga C, Bakouny Ziad, Ananda Guruprasad, Savignano Hunter, Lakshminarayanan Gitanjali, McClure Heather M, Silver Rebecca, Choueiri Toni K, Taplin Mary-Ellen, Park Peter J, Berchuck Jacob E
Abstract excerpt
BACKGROUND: The PARP inhibitor (PARPi) olaparib is approved for homologous recombination repair (HRR) gene-altered metastatic castration-resistant prostate cancer (mCRPC). However, there is significant heterogeneity in response to PARPi in patients with mCRPC. Better clinical biomarkers are needed to identify patients likely to benefit from PARPi. METHODS: Patients with prostate adenocarcinoma and panel...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.